Major pharmacy retailers pull heartburn medication Zantac from shelves after FDA detects carcinogens in samples of drug

ZantacWilfredo Lee/AP

  • Walgreens, CVS, and Rite Aid announced they are pulling the heartburn medication Zantac and other generic versions from their shelves, citing reports from the Food and Drug Administration of a cancer-causing contaminant in samples of the drug earlier this month.
  • The FDA detected low levels of nitrosodimethylamine (NDMA), which is a type of nitrosamine, in samples of the heartburn drug. Nitrosamines can increase a person's risk for cancer and are believed to be carcinogenic to humans.
  • While major pharmacy retailers are pulling the heartburn medication from their shelves, the companies that make the drug — including Sanofi, which makes brand-name Zantac — have yet to recall it.
  • Visit Business Insider's homepage for more stories.

Walgreens, CVS, and Rite Aid announced they are pulling the heartburn medication Zantac and other generic versions from their shelves, citing reports from the Food and Drug Administration of a cancer-causing contaminant in samples of the drug earlier this month.

The FDA detected low levels of nitrosodimethylamine (NDMA), which is a type of nitrosamine, in samples of the heartburn drug, which is also known as ranitidine.

See the rest of the story at Business Insider

NOW WATCH: Subway's 42,000 locations are the most of any fast-food chain on the planet, but franchise owners are taking a hit

See Also:

SEE ALSO: FDA announces voluntary recall of Sandoz ranitidine capsules following detection of an impurity



from Feedburner https://ift.tt/2nZNo1I
via IFTTT

Comments

Post a Comment

Popular posts from this blog

Remembering Joanne Pransky

A version of this post original appeared in TechCrunch’s weekly robotics newsletter, Actuator . It has been updated to include details about a new scholarship fund being raised in her honor.  I didn’t know Joanne Pransky personally, so when news of her death broke late last month, I reached out to my LinkedIn followers, asking if any of them did. “Yes,” answered one, “didn’t everyone?” Over decades of work, Pransky has left a lasting impact on the industry, bringing a uniquely human element to conversations about robotics and automation. “Joanne was the epitome of ‘Think Different,’” iRobot co-founder and Tertill CEO Helen Greiner told me over email. “She was a pioneer in calling attention to what robots would mean for society and what human society would mean for the robots.” Pransky proudly adopted the title of “the world’s first real Robotic Psychiatrist,” devoting herself to act as a conduit between humans and robots. “My ultimate goal is to help people understand their emotiona
Read more

Winging it

Image
Once again, your intrepid robotics reporter finds himself in the warm embrace of the Bay. To paraphrase Mark Twain, the warmest I was ever embraced was early summer in Santa Clara. I’m writing this from a juice place in Palo Alto (living the dream), having finished a pair of back-to-back meetings nearby. This week’s big Apple event brought me out here. As strange as it is to say, I’ve thus far missed the eye-burning smoke of Nova Scotia wildfires by traveling west to California. Very strange to view the apocalyptic New York skyline from afar. Though I suppose predictability is an element of climate change we’re going to be grappling with for . . . I don’t know, ever, probably. I’ve covered the Apple experience a bunch this week. If you have time to read only one thing I wrote on the Vision Pro headset , I’d recommend this . It’s mostly about positioning and market fit. There’s not a ton about the system that’s applicable to the manner of stuff you normally encounter in this newslet
Read more

Time for moderation?

Flexport CEO Ryan Petersen made it clear that while he was keen on buying Convoy because of the "incredible tech stack" it built, he wasn't buying its strategy. © 2023 TechCrunch. All rights reserved. For personal use only. from TechCrunch https://ift.tt/oB8wO3Q via IFTTT
Read more